• Age-related macular degeneration (AMD) is a progressive chronic disease of the central retina accounting for 8.7% of all blindness worldwide1.
• Early AMD patients exhibit moderate to severe impairment of dark adaptation (DA) even in the absence of visual acuity loss4–6.
• A test to probe rod function in dark adaptation can be used as a clinical outcome measure in studies tracking the progression of AMD, or more practically, a diagnostic tool targeting the identification of early AMD4.
• A patient’s rod function can be easily examined with Heru’s dark adaptation test which is billable to insurance (CPT 92284) and co-billable with visual fields, OCT and/or office visits.
Heru, the leader in AI-powered vision diagnostics, today announced it is showcasing the new PretestPro™ on its Heru wearable platform…
Rapid Adoption by Leading Eye Care Providers and Clinical Validation from Bascom Palmer Eye Institute, Fuel Accelerated Growth — Press…
Modern eye care practices are navigating growing patient volumes and rising operational complexity, often with limited time and resources. Finding…
Starting your own optometry practice or stepping into your first clinical role is a major milestone — and a big…
Take Advantage of the ADA Tax Credit While Transforming Your Practice In the rapidly evolving field of optometry, technological advancements are continuously…
Heru’s automated diagnostics, efficiency, and accuracy help optometrists focus on what matters most—exceptional care. The optometrist’s time with the patient…